Lushang Freda Pharmaceutical (600223) Fundamentals 2026 — P/E 32.7x, Revenue Analysis | SniperIQ
Lushang Freda Pharmaceutical (600223) is a CN-listed Healthcare company in Real Estate - Development with a market capitalization of ¥5.5B, trading at ¥5.39 on the SHH. This SniperIQ fundamentals page covers Lushang Freda Pharmaceutical's valuation (P/E 32.7x, P/B 1.3x), profitability (net margin 4.6%), revenue (¥3.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Lushang Freda Pharmaceutical's market cap?
Lushang Freda Pharmaceutical (600223) has a market capitalization of approximately ¥5.5B, trading at ¥5.39 on the SHH. Market cap moves with the live share price.
What is Lushang Freda Pharmaceutical's P/E ratio?
Lushang Freda Pharmaceutical's trailing twelve-month P/E ratio is 32.7x, with a price-to-book (P/B) of 1.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Lushang Freda Pharmaceutical?
Lushang Freda Pharmaceutical runs a net profit margin of 4.6%, a gross margin of 53.5%, and an operating margin of 5.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Lushang Freda Pharmaceutical generate?
Lushang Freda Pharmaceutical reported revenue of ¥3.6B for fiscal year 2025, with net income of ¥188M and earnings per share (EPS) of 0.18. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Lushang Freda Pharmaceutical pay a dividend?
Lushang Freda Pharmaceutical offers a trailing dividend yield of about 1.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Lushang Freda Pharmaceutical financially healthy?
Lushang Freda Pharmaceutical carries a debt-to-equity ratio of 0.04x and a current ratio of 4.61x, with a market beta of 0.93. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Lushang Freda Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Lushang Freda Pharmaceutical (600223) the key facts are: market cap ¥5.5B, P/E 32.7x, revenue ¥3.6B, 52-week range 4.89-8.78. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Lushang Freda Pharmaceutical's full fundamentals live
Get Lushang Freda Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.